Biodesix, Inc. disclosed preliminary financial results for 2025, demonstrating substantial revenue expansion across the full year and fourth quarter. The company reported full-year 2025 revenue of $88.5 million, representing 24% year-over-year growth, while fourth-quarter revenue reached $28.8 million, up 41% compared to the prior-year period. These results underscore accelerating momentum in the company's business performance during the latter part of the fiscal year.
In conjunction with its financial announcement, Biodesix reaffirmed guidance for achieving Adjusted EBITDA positivity in the fourth quarter of 2025, signaling progress toward profitability on an adjusted basis. The company's management team has scheduled participation in investor conferences scheduled for March 2026, providing an opportunity to detail operational achievements and strategic initiatives to institutional investors and analysts.
The earnings trajectory and margin improvement guidance reflect Biodesix's execution on its business plan during 2025. The company's participation in upcoming investor forums comes as it builds on this year's financial performance and positions itself for continued engagement with the investment community.